Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma.

Xu X, Tang L, Piao X, Zhan S, Chen Y, Feng P

DOI: 10.1371/journal.pone.0349044
Published: 2026
Container: PloS one
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1371/journal.pone.0349044,
  title = {Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma.},
  author = {Xu X and Tang L and Piao X and Zhan S and Chen Y and Feng P},
  year = {2026},
  journal = {PloS one},
  doi = {10.1371/journal.pone.0349044},
  url = {https://doi.org/10.1371/journal.pone.0349044}
}

RIS

TY  - JOUR
TI  - Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma.
AU  - Xu X
AU  - Tang L
AU  - Piao X
AU  - Zhan S
AU  - Chen Y
AU  - Feng P
PY  - 2026
JO  - PloS one
DO  - 10.1371/journal.pone.0349044
UR  - https://doi.org/10.1371/journal.pone.0349044
ER  -

APA

X, X., L, T., X, P., S, Z., Y, C., & P, F. (2026). Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma.. PloS one. https://doi.org/10.1371/journal.pone.0349044

Source records

pubmed · retrieved 2026-09-26T13:45:12.789Z
europe-pmc · retrieved 2026-09-26T13:45:12.791Z